| タイトル |
-
en
Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan
|
| その他のタイトル |
-
en
Confirmation of the 8th edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan
|
| 作成者 |
|
| アクセス権 |
open access |
| 権利情報 |
-
en
This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Oncology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10147-017-1107-0
|
| 主題 |
-
Other
en
AJCC/UICC TNM staging system
-
Other
en
Head and neck cancer
-
Other
en
Human papillomavirus
-
Other
en
Oropharynx
-
Other
en
p16
-
NDC
490
|
| 内容注記 |
-
Abstract
en
Background: Several studies have demonstrated that the 7th edition of the AJCC/UICC TNM staging classification system does not consistently distinguish between prognostic subgroups for human papillomavirus (HPV)-mediated oropharyngeal squamous cell carcinoma (OPSCC). The 8th edition of the AJCC/UICC TNM staging came into effect for use with HPV-mediated OPSCC on or after January 1, 2017. This study confirms that the 8th edition of the AJCC/UICC TNM staging system for HPV- mediated OPSCC accurately reflects disease outcomes. Patients and methods:We retrospectively analyzed 195 patients with OPSCC treated at Hokkaido University Hospital, Sapporo, Japan between 1998 and 2015. HPV status was evaluated by immunohistochemical analysis of p16. Results: Of the 195 OPSCC patients, 111 (56.9%) were p16 positive, and 84 (43.1%) were p16 negative. The 3-year overall survival rate (OS) was significantly lower in the p16-negative patients with stage III-IV in comparison with those with stage I-II (55.0% vs 93.1%, p<0.01). The 3-year OS did not differ significantly between stage I-II and stage III-IV in the p16-positive patients (86.7% vs 87.7%). According to the 8th edition of the AJCC/UICC TNM staging system, stage I-II and stage III could be differentiated on the basis of the 3-year OS in the p16-positive patients (90.9% vs 70.2%, p<0.01). Conclusions: The 7th edition of the AJCC/UICC TNM staging system is suitable for use with p16-negative patients; however, it does not effectively discriminate between p16-positive patients. Therefore, the 8th edition of the AJCC/UICC TNM staging system is more suitable for HPV-mediated OPSCC in Japan.
|
| 出版者 |
en
Springer
|
| 日付 |
|
| 言語 |
|
| 資源タイプ |
journal article |
| 出版タイプ |
AM |
| 資源識別子 |
HDL
http://hdl.handle.net/2115/71138
|
| 関連 |
-
isVersionOf
DOI
https://doi.org/10.1007/s10147-017-1107-0
-
PMID
28271391
|
| 収録誌情報 |
-
-
en
International journal of clinical oncology
-
巻22
号4
開始ページ682
終了ページ689
|
| ファイル |
|
| コンテンツ更新日時 |
2023-07-26 |
